Article
Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Mar 2015
Beuselinck Benoit, Job Sylvie, Becht Etienne, Karadimou Alexandra, Verkarre Virginie, Couchy Gabrielle, Giraldo Nicolas, Rioux-Leclercq Nathalie, Molinié Vincent, Sibony Mathilde, Elaidi Reza, Teghom Corinne, Patard Jean-Jacques, Méjean Arnaud, Fridman Wolf Herman, Sautès-Fridman Catherine, de Reyniès Aurélien, Oudard Stéphane, Zucman-Rossi Jessica
Abstract excerpt
PURPOSE: Selecting patients with metastatic clear-cell renal cell carcinoma (m-ccRCC) who might benefit from treatment with targeted tyrosine kinase inhibitors (TKI) is a challenge. Our aim was to identify molecular markers associated with outcome in patients with m-ccRCC treated with sunitinib. EXPERIMENTAL DESIGN: We performed global transcriptome analyses on 53 primary resected ccRCC tumors from patients who...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
